Opicapone Levodopa Combination for Motor Fluctuations
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Parkinson's disease, particularly levodopa therapy, often lead to unpredictable motor fluctuations, which are challenging to manage and significantly impact the quality of life for patients, with existing adjunctive therapies being ineffective for this severe condition.
Innovation Solution
The use of opicapone, a long-acting COMT inhibitor, in combination with levodopa, to reduce the degradation of levodopa and alleviate motor complications, including unpredictable motor fluctuations, by administering opicapone in conjunction with levodopa to patients experiencing these fluctuations.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If levodopa therapy is used to treat Parkinson's disease, then motor symptoms are suppressed effectively, but motor complications such as unpredictable motor fluctuations develop
Solution Approach 1:
The patent introduces an amine oxidase inhibitor (AOI) as an intermediary substance to modulate the metabolism of levodopa and dopamine. The AOI inhibits amine oxidase enzymes, thereby reducing the breakdown of dopamine and extending its action duration, which helps stabilize motor symptoms without causing the fluctuations associated with levodopa monotherapy
Solution Approach 2:
The patent changes the biochemical parameters of levodopa metabolism by combining it with an amine oxidase inhibitor. This combination alters the pharmacokinetic and pharmacodynamic parameters, extending the half-life of dopamine and creating a more stable plasma concentration profile, thereby preventing motor fluctuations
2Duration of action of stationary object
If long-term levodopa therapy is administered, then symptom control is maintained, but motor complications and quality of life deterioration occur
Solution Approach 1:
The patent applies prior cushioning by pre-emptively adding an amine oxidase inhibitor to the levodopa regimen before severe motor complications develop. This combination cushions against the development of motor fluctuations and dyskinesia that typically occur with long-term levodopa monotherapy, allowing extended treatment duration with reduced adverse effects
3Duration of action of moving object
If COMT inhibitors are used to extend levodopa half-life, then peak-trough variations are reduced, but treatment complexity increases
Solution Approach 1:
The patent changes the metabolic parameter of levodopa by introducing amine oxidase inhibition, which provides an alternative mechanism to COMT inhibition for extending levodopa half-life. This approach achieves similar clinical benefits in reducing peak-trough variations while potentially offering a simpler treatment profile depending on the specific AOI agent used
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Opicapone significantly reduces absolute off-time and improves quality of life by effectively managing unpredictable motor fluctuations, demonstrating efficacy in both 25 mg and 50 mg doses, with the 25 mg dose offering a cost-effective and side-effect-reducing option for patients with advanced Parkinson's disease.
Implementation Method 1
opicapone is a potent and long-acting COMT inhibitor that reduces the degradation of levodopa to the inactive metabolite 3-O-methyldopa
Implementation Method 2
Levodopa is able to cross the blood-brain barrier, where it is then converted to dopamine by the enzyme DOPA decarboxylase (DDC), thus increasing dopamine levels in the brain
Implementation Method 3
DDCIs prevent conversion of levodopa to dopamine in peripheral tissues
Data Source
AI summary
Opicapone, or a pharmaceutically acceptable derivative thereof, in combination with levodopa, or a pharmaceutically acceptable derivative thereof, for use in treating the symptoms of Parkinson's disease in a patient suffering from unpredictable motor fluctuations.